Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Barbara Degar, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Hospital for Sick Children
Toronto, Ontario, Canada
- Phoenix Children'S Hospital
Phoenix, Arizona, United States
- Arkansas Children'S Hospital
Little Rock, Arkansas, United States
- Children'S Hospital of Los Angeles
Los Angeles, California, United States
- University of California San Francisco Medical Center
San Francisco, California, United States
- Children'S National Medical Center
Washington D.C., District of Columbia, United States
- Boston Children'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mount Sinai Medical Center
New York, New York, United States
- Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
- the Children'S Hospital of Pennsylvania
Philadelphia, Pennsylvania, United States
- St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
- Texas Children'S Hospital
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2015
- Primary completion
- 31 Jan 2020
- Completion
- 31 Dec 2026
- Last update posted
- 23 Jun 2026
- Registered enrollment
- 25
- Registry id
- NCT02425904
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.